GET DAILY SIGNALSMirum Pharmaceuticals (MIRM) Reports +39.6% Year-Over-Year Sales Increase in Q3
Key Takeaways
- Mirum reported third quarter 2026 net product sales of $185.7 million, up 39.6% year over year and ahead of consensus estimates near $176–178 million.
- Diluted EPS came in at a loss of -$0.87, below consensus expectations, as the company sharply increased research and development spending.
- LIVMARLI net product sales reached $133.4 million, while bile acid medicines contributed $52.3 million, both posting double-digit growth.
- Management raised full-year 2026 net product sales guidance to $715–$720 million, above its prior outlook.
- The company's newest medicine, ATEBRIOZ for FOP, launched in the U.S. in October following its September approval.
Earnings Context and Why It Matters
Mirum Pharmaceuticals is a rare-disease biopharmaceutical company focused on rare liver and rare genetic conditions. Its commercial portfolio has expanded from one product to four approved medicines in recent years, making each quarterly report a key checkpoint on both revenue growth and the spending behind a broadening pipeline. The third quarter of 2026 marked the first full period following several important milestones, including the approval of ATEBRIOZ for FOP and positive late-stage data from the brelovitug and LIVMARLI programs. For investors, the results matter because they show whether strong commercial momentum can keep pace with a heavier investment cycle, and whether the company's push toward multiple future approvals is translating into durable top-line expansion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Mirum reported third quarter 2026 total net product sales of $185.7 million, a 39.6% increase from the prior-year period and above the consensus estimate of roughly $176–178 million. LIVMARLI (maralixibat), used to treat Alagille syndrome and PFIC, generated $133.4 million in net product sales, up about 45% year over year. Bile acid medicines, comprising CHOLBAM and CTEXLI, added $52.3 million, up approximately 28%. On the bottom line, the company posted a diluted loss of -$0.87 per share, wider than consensus estimates and a reversal from the small profit reported a year earlier. The swing largely reflected higher spending: research and development expenses rose to about $107.9 million from $43.0 million in the prior-year quarter, while selling, general, and administrative expenses climbed to roughly $88.9 million. The quarter's R&D outlays included development costs tied to brelovitug as well as acquired in-process research and development expenses. Mirum raised its full-year 2026 net product sales guidance to a range of $715–$720 million, an increase from its prior outlook and above the analyst consensus of approximately $698 million at the time. From what I see, this guidance lift underscores the strength in the commercial base.
Market Reaction and Investor Sentiment
Market reaction to the report reflected a mixed picture. Revenue beat expectations and guidance was raised, yet the wider-than-expected per-share loss highlighted the near-term cost of the company's pipeline investments. That combination — strong demand offset by heavier spending — typically leaves investors weighing commercial momentum against profitability timing. Heading into the report, sentiment had been supported by a series of clinical milestones, including positive Phase 3 data for brelovitug and the approval of ATEBRIOZ. The key risk factors investors continue to monitor are the pace of R&D escalation, the durability of LIVMARLI growth, and how quickly the company can convert its late-stage pipeline into approvals and commercial launches. I’m watching this closely as the balance between growth and investment plays out.
Forward Outlook and Key Factors to Monitor
Looking ahead, Mirum's management pointed to several near-term catalysts. The company expects brelovitug data from the AZURE-4 study in HDV during the fourth quarter, and volixibat data from the VANTAGE study in PBC in the first quarter of 2027. Investors should also watch the trajectory of the ATEBRIOZ launch in FOP, which began in October, and the planned regulatory submissions the company has outlined. Management cited five potential approvals and label expansions ahead, including submissions for volixibat, brelovitug, and a supplemental filing for LIVMARLI based on the EXPAND study. On the financial side, the key question is whether gross profit from the growing commercial base can eventually absorb the higher R&D bill. The company ended the quarter with unrestricted cash and investments of about $500 million, providing resources to fund continued development. Margin trends, expense discipline, and the pacing of clinical readouts will be the central factors to monitor over the coming quarters. In my view, the upcoming data readouts will be decisive for the longer-term story.
Using Tickeron’s AI Tools in My Workflow
In my analysis, I frequently rely on Tickeron’s AI Screener to quickly filter opportunities and compare names like MIRM against peers based on fundamentals, technical patterns, and AI signals. It helps surface comparable ideas without spending hours on manual reviews, and I find the customizable filters particularly useful when tracking pipeline-driven biotechs. The tool also integrates volatility and trend data that complements traditional research, allowing me to stay efficient while monitoring shifts in the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIRM's RSI Indicator climbs out of oversold territory
The RSI Oscillator for MIRM moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 13 similar instances when the indicator left oversold territory. In 12 of the 13 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on MIRM as a result. In 81 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on October 12, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 232 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 60 cases where MIRM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The 50-day moving average for MIRM moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for MIRM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MIRM's P/B Ratio (-542.223) is very low in comparison to the industry average of (3.104). P/E Ratio (-6.181) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company. which focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
Industry Biotechnology
Advertisement